Oxford, UK, January 12, 2017, Scientists from the Structural Genomics Consortium (SGC) and Oxford University report the first potent and selective chemical probe for the bromodomain of PCAF in an…
News
3D map of PC2 to jump-start drug discovery efforts in polycystic kidney disease
Oxford, UK, December 19, 2016, Scientists from the Structural Genomics Consortium (SGC) and Oxford University report a three-dimensional view of the Polycystin-2 (PC2), a protein that causes…
IMI project partner wins public-private collaboration award
The Structural Genomics Consortium (SGC), one of the project partners in IMI’s ULTRA-DD project, won the…
ULTRA-DD paves way for stronger cooperation with patients
Patients already have a big role in many IMI projects, for example by helping with patient recruitment or advising on best practices in clinical trials. Now the …
DiscoverX and the SGC Partner to Make an Annotated Collection of >600 Kinase Inhibitors Freely Available
Fremont, CA – February 29, 2016 – DiscoverX Corporation, the leading supplier of innovative cell-based assays and services for drug discovery and development, today announced its…
DPhG Young Investigator Award for Kilian Huber
During DPhG Annual Meeting 2015 which took place in Düsseldorf September 23-25, 2015, the German Pharmaceutical Society honoured a few up-and…
Patient Derived Cell Assays – The Case
The annual number of new drug approvals is trending upwards, the number of 'first-in-class' therapies has remained relatively constant — often fewer than 10 per year. For such new medicines…